Stryker (NYSE:SYK – Free Report) had its target price trimmed by JPMorgan Chase & Co. from $350.00 to $340.00 in a research note published on Friday,Benzinga reports. The firm currently has an overweight rating on the medical technology company’s stock.
Other equities research analysts have also issued research reports about the stock. Stifel Nicolaus decreased their price objective on shares of Stryker from $360.00 to $330.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. BTIG Research dropped their price objective on shares of Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a report on Friday. Piper Sandler reduced their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Citizens Jmp cut their price objective on Stryker from $400.00 to $390.00 and set a “market outperform” rating for the company in a research report on Friday. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Stryker in a research note on Wednesday, October 7th. Sixteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $355.44.
View Our Latest Stock Analysis on SYK
Stryker Price Performance
NYSE SYK opened at $291.56 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. The company’s 50 day simple moving average is $292.83 and its 200 day simple moving average is $324.51. Stryker has a 12 month low of $267.00 and a 12 month high of $389.33. The firm has a market capitalization of $111.83 billion, a PE ratio of 31.05, a P/E/G ratio of 1.89 and a beta of 0.78.
Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The business had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The business’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.19 EPS. As a group, equities research analysts forecast that Stryker will post 14.85 EPS for the current fiscal year.
Stryker Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a dividend of $0.88 per share. The ex-dividend date was Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is presently 37.49%.
Insider Buying and Selling at Stryker
In other Stryker news, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 351,267 shares of company stock worth $118,197,701 in the last three months. 4.60% of the stock is currently owned by company insiders.
Institutional Trading of Stryker
A number of hedge funds and other institutional investors have recently modified their holdings of SYK. Kestra Private Wealth Services LLC lifted its holdings in shares of Stryker by 3.1% during the third quarter. Kestra Private Wealth Services LLC now owns 28,721 shares of the medical technology company’s stock worth $7,910,000 after purchasing an additional 868 shares during the period. Bfsg LLC boosted its position in shares of Stryker by 1.0% in the third quarter. Bfsg LLC now owns 12,558 shares of the medical technology company’s stock worth $3,458,000 after acquiring an additional 122 shares during the last quarter. Focused Wealth Management Inc increased its position in shares of Stryker by 28.5% in the third quarter. Focused Wealth Management Inc now owns 1,191 shares of the medical technology company’s stock worth $328,000 after acquiring an additional 264 shares in the last quarter. Rakuten Investment Management Inc. lifted its position in Stryker by 10.6% during the 3rd quarter. Rakuten Investment Management Inc. now owns 62,389 shares of the medical technology company’s stock worth $17,392,000 after acquiring an additional 5,976 shares in the last quarter. Finally, AIA Group Ltd increased its stake in shares of Stryker by 230.4% in the third quarter. AIA Group Ltd now owns 46,593 shares of the medical technology company’s stock worth $12,831,000 after buying an additional 32,493 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.
Trending Headlines about Stryker
Here are the key news stories impacting Stryker this week:
- Positive Sentiment: JPMorgan lowered its price target from $350 to $340 but maintained an “overweight” rating, implying substantial upside from recent trading levels. Barclays also reaffirmed its “buy” rating, signaling continued confidence in Stryker’s longer-term medical-device prospects. JPMorgan Stryker rating Barclays reaffirms buy rating
- Neutral Sentiment: Analyst sentiment is mixed: Citizens JMP, Citigroup, TD Cowen, and Barclays reportedly trimmed their price targets, while Canaccord Genuity downgraded Stryker to “hold.” The changes reflect more cautious expectations rather than a broad rejection of the company’s fundamentals.
- Negative Sentiment: Stryker’s latest results fell short of forecasts. Adjusted earnings were $3.52 per share versus a $3.55 consensus estimate, while revenue of $6.52 billion missed expectations of $6.62 billion. Although revenue increased 7.6% year over year, the miss and a reset of third-quarter guidance weakened the near-term outlook. Stryker Q3 2026 earnings call transcript
- Negative Sentiment: Health-insurance headwinds were cited as an additional concern, contributing to lower fair-value estimates and multiple price-target cuts. Deutsche Bank reduced its target to $275 from $315 while retaining a “hold” rating. The stock also broke below its 50-day moving average after the disappointing report, adding technical pressure. Stryker stock down on Q3 misses Deutsche Bank adjusts Stryker price target
About Stryker
Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.
The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.
Read More
- Five stocks we like better than Stryker
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
